These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26164949)

  • 21. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.
    Ternette N; Tippler B; Uberla K; Grunwald T
    Vaccine; 2007 Oct; 25(41):7271-9. PubMed ID: 17825960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Potential of Prefusion RSV F-specific Antibodies.
    Rossey I; McLellan JS; Saelens X; Schepens B
    Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice.
    Singh SR; Dennis VA; Carter CL; Pillai SR; Moore EG
    Viral Immunol; 2007; 20(2):261-75. PubMed ID: 17603843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
    Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
    Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats.
    Smith G; Raghunandan R; Wu Y; Liu Y; Massare M; Nathan M; Zhou B; Lu H; Boddapati S; Li J; Flyer D; Glenn G
    PLoS One; 2012; 7(11):e50852. PubMed ID: 23226404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
    Harshbarger W; Abeyrathne PD; Tian S; Huang Y; Chandramouli S; Bottomley MJ; Malito E
    MAbs; 2021; 13(1):1955812. PubMed ID: 34420474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
    Haynes LM; Caidi H; Radu GU; Miao C; Harcourt JL; Tripp RA; Anderson LJ
    J Infect Dis; 2009 Aug; 200(3):439-47. PubMed ID: 19545210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.
    De Baets S; Schepens B; Sedeyn K; Schotsaert M; Roose K; Bogaert P; Fiers W; Saelens X
    J Virol; 2013 Mar; 87(6):3314-23. PubMed ID: 23302879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of recombinant influenza A virus as a vector expressing respiratory syncytial virus fusion protein epitopes.
    Zhang P; Gu H; Bian C; Liu N; Li Z; Duan Y; Zhang S; Wang X; Yang P
    J Gen Virol; 2014 Sep; 95(Pt 9):1886-1891. PubMed ID: 24914066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virus.
    Eyles JE; Johnson JE; Megati S; Roopchand V; Cockle PJ; Weeratna R; Makinen S; Brown TP; Lang S; Witko SE; Kotash CS; Li J; West K; Maldonado O; Falconer DJ; Lees C; Smith GJ; White P; Wright P; Loudon PT; Merson JR; Jansen KU; Sidhu MK
    J Infect Dis; 2013 Jul; 208(2):319-29. PubMed ID: 23596321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection.
    Zhang Y; Zhou Z; Zhu SL; Zu X; Wang Z; Zhang LK; Wang W; Xiao G
    Antiviral Res; 2019 May; 165():11-22. PubMed ID: 30822450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.
    Krarup A; Truan D; Furmanova-Hollenstein P; Bogaert L; Bouchier P; Bisschop IJM; Widjojoatmodjo MN; Zahn R; Schuitemaker H; McLellan JS; Langedijk JPM
    Nat Commun; 2015 Sep; 6():8143. PubMed ID: 26333350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.
    Boyington JC; Joyce MG; Sastry M; Stewart-Jones GB; Chen M; Kong WP; Ngwuta JO; Thomas PV; Tsybovsky Y; Yang Y; Zhang B; Chen L; Druz A; Georgiev IS; Ko K; Zhou T; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2016; 11(7):e0159709. PubMed ID: 27463224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
    Crowe JE; Firestone CY; Crim R; Beeler JA; Coelingh KL; Barbas CF; Burton DR; Chanock RM; Murphy BR
    Virology; 1998 Dec; 252(2):373-5. PubMed ID: 9878616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies.
    Garg R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2015 Mar; 33(11):1338-44. PubMed ID: 25637860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
    Bukreyev A; Yang L; Fricke J; Cheng L; Ward JM; Murphy BR; Collins PL
    J Virol; 2008 Dec; 82(24):12191-204. PubMed ID: 18842713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
    Nelson CL; Tang RS; Stillman EA
    Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic.
    Dollenmaier G; Mosier SM; Scholle F; Sharma N; McKnight KL; Lemon SM
    Virology; 2001 Mar; 281(2):216-30. PubMed ID: 11277694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.